Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics and maximum tolerated dose of TAK-733 in patients with advanced, nonhematologic tumors. The expansion stage of the study will evaluate evidence of antitumor activity of TAK-733 in patients with advanced metastatic melanoma.

Timeline

Start

2009-12

Primary completion

2013-04

Completion

2013-06

Drugs

Indications